anti-AAV2, human chimeric, A20-h1
Dot blot analysis of AAV2 and AAV3 native (1E+09-1E+10 capsids) and denatured (1E+10 capsids, denatured at 95°C for 10 min in sample buffer) capsids with mouse monoclonal AAV2 antibody clone A20 and human chimeric AAV2 antibody clone A20-h1.
The nitrocellulose membrane was blocked with 5% milk in PBST for 45 min at RT. The primary antibody anti-AAV2 (intact particle) mouse monoclonal, A20 (Cat. No. 61055) or anti-AAV2, human chimeric, A20-h1 (Cat. No. 692379) was diluted in blocking buffer (antibody concentration 100 ng/ml) and incubated for 1.5 h at RT. The secondary antibody anti-mouse IgG goat polyclonal, HRP conjugate or anti-human IgG goat polyclonal, HRP conjugate was also diluted in blocking buffer (antibody concentration 200 ng/ml) and incubated for 1.5 h at RT. The bands were visualized by chemiluminescent detection using Pierce™ ECL Western Blotting Substrate.
Dot blot analysis of AAV1-AAV9, AAVrh10, AAVrh74, AAVDJ native (1E+09-1E+10 capsids) and denatured (1E+10 capsids, denatured at 95°C for 10 min in sample buffer) capsids.
The nitrocellulose membrane was blocked with 5% milk in PBST for 45 min at RT. The primary antibody anti-AAV2, human chimeric, A20-h1 (Cat. No. 692379) was diluted in blocking buffer (antibody concentration 100 ng/ml) and incubated for 1.5 h at RT. The secondary antibody anti-human IgG goat polyclonal, HRP conjugate was also diluted in blocking buffer (antibody concentration 200 ng/ml) and incubated for 1 h at RT. The bands were visualized by chemiluminescent detection using Pierce™ ECL Western Blotting Substrate.
Neutralization of AAV3 with mouse monoclonal AAV2 antibody clone A20 (A) and human chimeric AAV2 antibody clone A20-h1 (B) by using AAV3-NanoLuc® viral particles from Promega. (A) anti-AAV2 (intact particle) mouse monoclonal, A20 (Cat. No. 61055) or (B) anti-AAV2, human chimeric, A20-h1 (Cat. No. 692379) were preincubated with AAV3-NanoLuc® viral particles for 30 min at RT at 300 rpm (antibody concentrations 0.2-3,000 ng/ml). HEK293 cells (100 µl) were plated at 200,000 cells/ml in DMEM + 1% FCS. Virus-antibody-mix (20 µl) was added to the cells and incubated for 16-24 h at 37°C. Extracellular NanoLuc Inhibitor and Nano-Glo® Live Cell Assay System (Promega) was added to the wells and incubated for 5 min at RT at 300 rpm. Luminescence was measured using an ID5-Reader and plotted with Softmax Pro 7.1 software to determine the EC50 values.
View more
Neutralization of AAV2 with mouse monoclonal AAV2 antibody clone A20 (A) and human chimeric AAV2 antibody clone A20-h1 (B) by using AAV2-NanoLuc® viral particles from Promega. (A) anti-AAV2 (intact particle) mouse monoclonal, A20 (Cat. No. 61055) or (B) anti-AAV2, human chimeric, A20-h1 (Cat. No. 692379) were preincubated with AAV2-NanoLuc® viral particles for 30 min at RT at 300 rpm (antibody concentrations 0.2-3,000 ng/ml). HEK293 cells (100 µl) were plated at 200,000 cells/ml in DMEM + 1% FCS. Virus-antibody-mix (20 µl) was added to the cells and incubated for 16-24 h at 37°C. Extracellular NanoLuc Inhibitor and Nano-Glo® Live Cell Assay System (Promega) was added to the wells and incubated for 5 min at RT at 300 rpm. Luminescence was measured using an ID5-Reader and plotted with Softmax Pro 7.1 software to determine the EC50 values.
View more
Comparison of binding affinity and neutralization activity of anti-AAV2 antibodies (mouse monoclonal A20, mouse recombinant A20R and human chimeric A20-h1).
View more
Dot blot analysis of AAV2 and AAV3 native (1E+09-1E+10 capsids) and denatured (1E+10 capsids, denatured at 95°C for 10 min in sample buffer) capsids with mouse monoclonal AAV2 antibody clone A20 and human chimeric AAV2 antibody clone A20-h1.
The nitrocellulose membrane was blocked with 5% milk in PBST for 45 min at RT. The primary antibody anti-AAV2 (intact particle) mouse monoclonal, A20 (Cat. No. 61055) or anti-AAV2, human chimeric, A20-h1 (Cat. No. 692379) was diluted in blocking buffer (antibody concentration 100 ng/ml) and incubated for 1.5 h at RT. The secondary antibody anti-mouse IgG goat polyclonal, HRP conjugate or anti-human IgG goat polyclonal, HRP conjugate was also diluted in blocking buffer (antibody concentration 200 ng/ml) and incubated for 1.5 h at RT. The bands were visualized by chemiluminescent detection using Pierce™ ECL Western Blotting Substrate.
Dot blot analysis of AAV1-AAV9, AAVrh10, AAVrh74, AAVDJ native (1E+09-1E+10 capsids) and denatured (1E+10 capsids, denatured at 95°C for 10 min in sample buffer) capsids.
The nitrocellulose membrane was blocked with 5% milk in PBST for 45 min at RT. The primary antibody anti-AAV2, human chimeric, A20-h1 (Cat. No. 692379) was diluted in blocking buffer (antibody concentration 100 ng/ml) and incubated for 1.5 h at RT. The secondary antibody anti-human IgG goat polyclonal, HRP conjugate was also diluted in blocking buffer (antibody concentration 200 ng/ml) and incubated for 1 h at RT. The bands were visualized by chemiluminescent detection using Pierce™ ECL Western Blotting Substrate.
Neutralization of AAV3 with mouse monoclonal AAV2 antibody clone A20 (A) and human chimeric AAV2 antibody clone A20-h1 (B) by using AAV3-NanoLuc® viral particles from Promega. (A) anti-AAV2 (intact particle) mouse monoclonal, A20 (Cat. No. 61055) or (B) anti-AAV2, human chimeric, A20-h1 (Cat. No. 692379) were preincubated with AAV3-NanoLuc® viral particles for 30 min at RT at 300 rpm (antibody concentrations 0.2-3,000 ng/ml). HEK293 cells (100 µl) were plated at 200,000 cells/ml in DMEM + 1% FCS. Virus-antibody-mix (20 µl) was added to the cells and incubated for 16-24 h at 37°C. Extracellular NanoLuc Inhibitor and Nano-Glo® Live Cell Assay System (Promega) was added to the wells and incubated for 5 min at RT at 300 rpm. Luminescence was measured using an ID5-Reader and plotted with Softmax Pro 7.1 software to determine the EC50 values.
Neutralization of AAV2 with mouse monoclonal AAV2 antibody clone A20 (A) and human chimeric AAV2 antibody clone A20-h1 (B) by using AAV2-NanoLuc® viral particles from Promega. (A) anti-AAV2 (intact particle) mouse monoclonal, A20 (Cat. No. 61055) or (B) anti-AAV2, human chimeric, A20-h1 (Cat. No. 692379) were preincubated with AAV2-NanoLuc® viral particles for 30 min at RT at 300 rpm (antibody concentrations 0.2-3,000 ng/ml). HEK293 cells (100 µl) were plated at 200,000 cells/ml in DMEM + 1% FCS. Virus-antibody-mix (20 µl) was added to the cells and incubated for 16-24 h at 37°C. Extracellular NanoLuc Inhibitor and Nano-Glo® Live Cell Assay System (Promega) was added to the wells and incubated for 5 min at RT at 300 rpm. Luminescence was measured using an ID5-Reader and plotted with Softmax Pro 7.1 software to determine the EC50 values.
Comparison of binding affinity and neutralization activity of anti-AAV2 antibodies (mouse monoclonal A20, mouse recombinant A20R and human chimeric A20-h1).
- Recombinant chimeric (human Fc region)
- Suitable for dot blot, neutralization assay and serology ELISA
- Reacts with AAV2 and AAV3 intact capsids
- Isotype: IgG1
Product description
| Quantity | 1 ml |
|---|---|
| Antibody Type | Monoclonal |
| Host | Recombinant chimeric (human Fc region) |
| Isotype | IgG1 |
| Conjugate | Unconjugated |
| Application | Dot blot, Neutralization assay, Serology ELISA |
| Purification | Affinity chromatography |
| Reactivity | AAV2, AAV3 |
| No reactivity | AAV1, AAV4, AAV5, AAV6, AAV8, AAV9, AAVDJ, AAVrh10, AAVrh74 |
| Storage | 2-8°C |
| Intended use | Research use only |
| Clone | A20-h1 |
| Immunogen | AAV2 capsids |
| Concentration | 50 µg/ml |
| Formulation | PBS, pH 7.4 with 0.09% sodium azide and 0.5% BSA |
| Binding affinity | KD value (AAV2) = 1.2E-10 M KD value (AAV3) = 9.3E-11 M |
| Synonym | Adeno-associated virus 2; AAV-2 |
Applications
| Tested applications | Tested dilutions |
|---|---|
| Serology Assay | 1-4 µg/ml (1:12.5-1:50; AAV2 ELISA) |
| Dot Blot | 0.1 µg/ml (1:500; non-denaturing conditions) |
| Neutralization Assay | EC50 ~8 ng/ml (AAV2) and ~29 ng/ml (AAV3) - assay dependent |
Background
Our human chimeric AAV antibodies are derived from our mouse monoclonal AAV antibodies and are a combination of the mouse antigen binding region and a human Fc region. Therefore, it provides the well-known characteristics of the corresponding mouse monoclonal antibody (anti-AAV2, A20, Cat. No. 61055) like cross-reactivity and neutralization activity combined with a human Fc region allowing the use in an anti-human secondary antibody detection system.
Many humans in the general population have developed antibodies against AAV as a result of naturally acquired infections, which might affect efficacy and safety of the gene transfer using AAV vectors. Therefore, testing for pre-existing AAV antibodies in patient sera is an indispensable step for the selection of patients for AAV gene therapy clinical trials.
Our human chimeric AAV antibodies are close to the human derived samples, making them the ideal positive control for reproducible and comparable serological assays.
Limited Use Label License: Research Use Only
Product is exclusively owned to PROGEN Biotechnik GmbH. The use of these products for the development, manufacturing and sale of secondary products/derivatives which are based on the purchased products and/or which include the purchased product require a royalty based sub-license agreement.
Downloads
Q & A's
Customer Reviews
Login
FAQs
The human chimeric AAV antibodies have the same variable region as our mouse monoclonal antibodies but instead a human constant region.
Yes, they show the same cross-reactivity as their mouse monoclonal versions. The table below shows where cross-reactivity takes place.
| Human Chimeric Antibody | Clone | AAV1 | AAV2 | AAV3 | AAV4 | AAV5 | AAV6 | AAV7 | AAV8 | AAV9 | AAVrh10 | AAVrh74 | AAVDJ |
| Anti-AAV1 | ADK1a-h1 | X | X | n.a.* | |||||||||
| Anti-AAV2 | A20-h1 | X | X | n.a.* | |||||||||
| Anti-AAV5 | ADK5b-h1 | X | n.a.* | ||||||||||
| Anti-AAV5 | ADK5b-h2 | X | n.a.* | ||||||||||
| Anti-AAV8 | ADK8-h1 | X | X | X | X | X | |||||||
| Anti-AAV9 | ADK9-h1 | n.a.* | X |
*n.a.: not analyzed
The binding affinity of the human chimeric antibodies to different AAV serotypes was tested and compared to the corresponding mouse monoclonal antibodies using biolayer interferometry (BLI) analysis. The table below shows the results.
| Serotype | Antibody Clone | Binding Affinity (KD Value) |
| AAV1 | ADK1a | <1.0E-12 M |
| ADK1a-h1 | 8.8E-12 M | |
| AAV2 | A20 | 2.6E-11 M |
| A20-h1 | 1.2E-10 M | |
| A20R | <1.0E-12 M | |
| AAV3 | A20 | <1.0E-12 M |
| A20-h1 | 9.3E-11 M | |
| A20R | <1.0E-12 M | |
| AAV5 | ADK5a | 4.9E-11 M |
| ADK5b | 6.0E-11 M | |
| ADK5b-h1 | 8.1E-11 M | |
| ADK5b-h2 | 3.6E-11 M | |
| AAV6 | ADK1 | <1.0E-12 M |
| ADK1a-h1 | 5.9E-11 M | |
| AAV8 | ADK8 | <1.0E-12 M |
| ADK8-h1 | <1.0E-12 M | |
| AAV9 | ADK9-1R | <1.0E-12 M |
| ADK9-h1 | 7.0E-11 M | |
| AAVrh10 | ADK8 | <1.0E-12 M |
| ADK8-h1 | <1.0E-12 M | |
| AAVrh74 | ADK8 | <1.0E-12 M |
| ADK8-h1 | <1.0E-12 M |
The lower the KD value the higher the binding affinity. The detection limit is 1.0E-12 M.
Related Products
- Consists of fully assembled, empty AAV2 capsids
- Represents serotype-specific conformational epitopes
- Reliable positive control for ELISA
- Fully assembled, empty AAV2 capsids
- Serotype-specific conformational epitopes
- Reliable positive control for dot blot, western blot, ELISA
- Quality controlled for purity, AAV titer and filling grade
- Alignment to internal reference standard material
For US shipment, the packages are only sent out for delivery on Mondays and Tuesdays, in the EU from Monday until Wednesday.
- ELISA for quantitation of AAV2 capsids
- Detection of full and empty AAV2 capsids
- A20 antibody is used as capture and detection antibody
- ELISA for quantitation of AAV2 capsids
- Detection of full and empty AAV2 capsids
- A20R antibody is used as capture and detection antibody
• Useful for ratio analysis
• Precise molar concentration
• Suitable for WB, dot blot, CE, SDS PAGE
- get results in less than 2 hours and increase your daily sample throughput
- easy workflow & process integration
- same accuracy and reproducibility as the standard AAV2 Titration ELISAs
- A20R antibody is used as capture and detection antibody
- Consists of fully assembled, empty AAV3 capsids
- Represents serotype-specific conformational epitopes
- Reliable positive control for ELISA
- ELISA for quantitation of AAV3 capsids
- Detection of full and empty AAV3 capsids
- A20R antibody is used as capture and detection antibody
- Mouse monoclonal
- Suitable for ELISA, ICC/IF, IP and WB
- Reacts with VP1 of AAV1, AAV2, AAV3, AAV5, AAV6, AAV7, AAV8, AAV9 and AAVDJ
- Isotype: IgG2a
- Mouse monoclonal
- Suitable for ICC/IF, IP and WB
- Reacts with AAV2 and AAVDJ
- Isotype: IgG1
- Mouse monoclonal
- Suitable for affinity chromatography, dot blot, ICC/IF, IP and WB
- Reacts with denatured VP1, VP2, VP3 proteins of AAV1, 2, 3, 5, 6, 7, 8, 9, rh10, DJ
- Isotype: IgG1
- Rabbit polyclonal
- Suitable for ELISA, ICC/IF, IP and WB
- Reacts with AAV1, AAV2, AAV3, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrh10, AAVDJ and AAVrh74, weakly with AAV4
- Strong affinity for denatured capsid proteins
- Weak affinity for native capsids
- Purified, lyophilized
- Mouse monoclonal
- Suitable for dot blot, ELISA, ICC and neutralization assay
- Reacts with AAV2, AAV2 7m8 and AAV3 intact particles
- Isotype: IgG3
- Purified, lyophilized
- Mouse monoclonal
- Suitable for WB
- Reacts with AAV2 Rep40, Rep52, Rep68 and Rep78
- Isotype: IgG1
- Mouse monoclonal
- Suitable for WB
- Reacts with AAV2 Rep40, Rep52, Rep68 and Rep78
- Isotype: IgG1
- Recombinant chimeric (human Fc region)
- Suitable for dot blot, neutralization assay and serology ELISA
- Reacts with AAV2 and AAV3 intact capsids
- Isotype: IgG1
- Highly effective density gradient media for the separation of full and empty AAV particles
- Designed for the purification of viruses (such as AAV)
- Useful to isolate different cell types and organelles
- Ready-made, sterile and endotoxin-tested solution of iodixanol